Monitoring ctDNA RAS Mutational Status in Metastatic Colorectal Cancer: A Trial Protocol of RAS-trace and RAS-trace-2 Studies-Reference-Cited by-同舟云学术

Monitoring ctDNA RAS Mutational Status in Metastatic Colorectal Cancer: A Trial Protocol of RAS-trace and RAS-trace-2 Studies

Published:2024-04-25 Issue:2 Volume:8 Page:132-136
ISSN:2432-3853
Container-title:Journal of the Anus, Rectum and Colon
language:en
Short-container-title:J Anus Rectum Colon

Author:

Kataoka Kozo¹,Yamada Takeshi²,Shiozawa Manabu³,Takase Naoto⁴,Ito Kazuma¹,Yamazaki Kentaro⁵,Watanabe Jun⁶,Kudo Toshihiro⁷,Suto Takeshi⁸,Matsumoto Toshihiko⁹,Murata Kohei¹⁰,Suwa Yusuke⁶,Boku Shogen¹¹,Yasui Hisateru¹²,Matsuhashi Nobuhisa¹³,Maeda Atsuyuki¹⁴,Sugimoto Kiichi¹⁵,Matsumoto Yusuke¹⁶,Yokota Mitsuru¹⁷,Fredebohm Johannes¹⁸,Mori Keita¹⁹,Ikeda Masataka¹

Affiliation:

1. Division of Lower GI Surgery, Department of Gastroenterological Surgery, Hyogo Medical University

2. Department of Gastrointestinal and Hepato-Billiary-Pancreatic Surgery, Nippon Medical School

3. Department of Gastrointestinal Surgery, Kanagawa Cancer Center

4. Department of Medical Oncology, Takarazuka City Hospital

5. Division of Gastrointestinal Oncology, Shizuoka Cancer Center

6. Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center

7. Department of Medical Oncology, Osaka International Cancer Institute

8. Department of Gastroenterological Surgery, Yamagata Prefectural Central Hospital

9. Department of Medical Oncology, Ichinomiya Nishi Hospital

10. Department of Surgery, Kansai Rosai Hospital

11. Cancer Treatment Center, Kansai Medical University Hospital

12. Department of Medical Oncology, Kobe City Medical Center General Hospital

13. Department of Gastroenterological Surgery and Pediatric Surgery, Gifu Graduate School of Medicine

14. Department of Surgery, Ogaki Municipal Hospital

15. Department of Coloproctological Surgery, Juntendo University, Faculty of Medicine

16. Department of Surgery, Japanese Red Cross Society Himeji Hospital

17. Department of General Surgery, Kurashiki Central Hospital

18. Sysmex Inostics GmbH

19. Department of Biostatistics, Clinical Research Center, Shizuoka Cancer Center

Publisher

The Japan Society of Coloproctology

Link

https://www.jstage.jst.go.jp/article/jarc/8/2/8_2023-051/_pdf

Reference13 articles.

1. 1. Watanabe J, Muro K, Shitara K, et al. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2023 Apr; 329 (15): 1271-82.

2. 2. Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Jan; 34 (1): 10-32.

3. 3. Yoshino T, Cervantes A, Bando H, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. ESMO Open. 2023 Jun; 8 (3): 101558.

4. 4. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018 Feb; 15 (2): 81-94.

5. 5. Cremolini C, Rossini D, Dell'Aquila E, et al. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. JAMA Oncology. 2019 Mar; 5 (3): 343-50.